DCM
LVTX

DAFNA Capital Management’s LAVA Therapeutics LVTX Stock Holding History

DAFNA Capital Management’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-128,335
Closed -$379K – 90
2022
Q2 		$379K Sell
128,335
-10,997
-8% -$38.1K 0.1% 81
2022
Q1 		$613K Hold
139,332
– – 0.16% 80
2021
Q4 		$766K Hold
139,332
– – 0.19% 71
2021
Q3 		$825K Buy
139,332
+3,700
+3% +$26.6K 0.22% 69
2021
Q2 		$1.48M Buy
+135,632
New +$1.68M 0.31% 63

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DAFNA Capital Management's LVTX Position: Q3 2022 in Review

DAFNA Capital Management sold out of LAVA Therapeutics (LVTX) in Q3 2022, closing a stake of 128,335 shares — an estimated $379K sold.

DAFNA Capital Management first reported a position in LVTX in Q2 2021 and held it in 5 quarters. The position peaked at $1.48M in Q2 2021. 13 funds tracked by Wall St. Rank hold LVTX as of Q3 2022.

  • DAFNA Capital Management reported no remaining LAVA Therapeutics position as of Q3 2022 after selling out during the quarter.
  • DAFNA Capital Management sold 128,335 LAVA Therapeutics shares in Q3 2022, an estimated $379K.
  • DAFNA Capital Management first reported a position in LAVA Therapeutics in Q2 2021 and held it in 5 quarters.
  • DAFNA Capital Management's LAVA Therapeutics position peaked at $1.48M in Q2 2021.
  • 13 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2022.

Based on DAFNA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.